Drilldown: Medicines
Use the filters below to narrow your results.
generic:
None (1) ·
Amantadine (1) ·
Apomorphine (1) ·
Benztropine (1) ·
Biperiden (1) ·
Brivaracetam (1) ·
Bromocriptine (1) ·
Cabergoline (1) ·
Cannabidiol (1) ·
Carbidopa/levodopa (1) ·
Cenobamate (1) ·
Clobazam (1) ·
Entacapone (1) ·
Eslicarbazepine (1) ·
Ethosuximide (1) ·
Felbamate (1) ·
Fenfluramine (1) ·
Fosphenytoin (1) ·
Lacosamide (1) ·
Levodopa (1) ·
Opicapone (1) ·
Perampanel (1) ·
Phenobarbital (1) ·
Phenytoin (1) ·
Rasagiline (1) ·
Rotigotine (1) ·
Rufinamide (1) ·
Safinamide (1) ·
Selegiline (1) ·
Stiripentol (1) ·
Tiagabine (1) ·
Tolcapone (1) ·
Trihexyphenidyl (1) ·
Valproic acid (1) ·
Vigabatrin (1) ·
Zonisamide (1)
brand:
None (1) ·
Akineton (1) ·
Apokyn (1) ·
Aptiom (1) ·
Artane (1) ·
Azilect (1) ·
Banzel (1) ·
Briviact (1) ·
Cerebyx (1) ·
Cogentin (1) ·
Comtan (1) ·
Depakote (1) ·
Diacomit (1) ·
Dilantin (1) ·
Dostinex (1) ·
Eldepryl (1) ·
Epidiolex (1) ·
Felbatol (1) ·
Fintepla (1) ·
Fycompa (1) ·
Gabitril (1) ·
Luminal (1) ·
Neupro (1) ·
Onfi (1) ·
Ongentys (1) ·
Parlodel (1) ·
Rexulti (1) ·
Sabril (1) ·
Sinemet (1) ·
Symmetrel (1) ·
Tasmar (1) ·
Vimpat (1) ·
Xadago (1) ·
Xcopri (1) ·
Zarontin (1) ·
Zonegran (1)
classes: (Click arrow to add another value)
mechanism:
AMPA receptor antagonist (1) ·
Central and peripheral COMT inhibitor (1) ·
D1/D2/D3 receptor agonist (1) ·
D2 agonist; D1 partial agonist (1) ·
D2 receptor agonist (1) ·
Dopamine precursor (1) ·
Dopamine precursor + DOPA decarboxylase inhibitor (1) ·
GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) ·
GABA reuptake inhibitor (GAT-1 blocker) (1) ·
GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) ·
GABAA potentiator and direct activator (1) ·
Irreversible GABA-T inhibitor (1) ·
Irreversible selective MAO-B inhibitor (2) ·
MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) ·
Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) ·
Muscarinic receptor antagonist (1) ·
Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) ·
NMDA antagonist; dopamine releasing agent (1) ·
NMDA antagonist; GABAA potentiator (1) ·
Non-selective dopamine receptor agonist (1) ·
Once-daily COMT inhibitor (1) ·
Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1) ·
Peripheral COMT inhibitor (1) ·
Prodrug of phenytoin; sodium channel blocker (1) ·
Selective M1 muscarinic antagonist (1) ·
Serotonin releaser; sigma-1 agonist (1) ·
Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) ·
Sodium channel blocker (2) ·
Sodium channel blocker; GABAA positive allosteric modulator (1) ·
Sodium channel modulator (1) ·
Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) ·
SV2A ligand (higher affinity than levetiracetam) (1) ·
T-type calcium channel blocker (1)
uses:
None (35) ·
Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1)
starting dose:
preparations:
duration:
halflife:
Showing below up to 36 results in range #1 to #36.